Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATP4A | P20648 | 3/20 | 0.40 |
| ▸ | ATP4B | P51164 | 3/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649258 | 0.96 | C5AR1 (0.45) | C5AR1MAPTCACNA2D1TNK2BCHE | |
| SCHEMBL649083 | 0.95 | C5AR1 (0.42) | C5AR1MAPTCACNA2D1TNK2BCHE | |
| SCHEMBL650505 | 0.95 | C5AR1 (0.43) | C5AR1MAPTATP4AATP4BCACNA2D1 | |
| SCHEMBL649417 | 0.94 | C5AR1 (0.43) | C5AR1MAPTCACNA2D1BCHEHPGD | |
| SCHEMBL651401 | 0.94 | C5AR1 (0.42) | C5AR1MAPTCACNA2D1BCHEHPGD | |
| SCHEMBL648177 | 0.94 | C5AR1 (0.42) | C5AR1MAPTCACNA2D1TNK2BCHE | |
| SCHEMBL652044 | 0.93 | C5AR1 (0.43) | C5AR1MAPTCACNA2D1BCHETSHR | |
| SCHEMBL648091 | 0.93 | C5AR1 (0.44) | C5AR1MAPTATP4AATP4BBCHE | |
| SCHEMBL649888 | 0.92 | C5AR1 (0.40) | C5AR1MAPTATP4AATP4BCACNA2D1 | |
| SCHEMBL650373 | 0.92 | TP53 (0.41) | C5AR1MAPTBCHEHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |